EU Offers Practical Guide To Help Pharma With Nitrosamine Evaluations
Guide Explains Steps Needed For Risk Evaluations And Confirmatory Testing
Executive Summary
The EU guide covers medicines authorized at the national level and under the mutual recognition and decentralized procedures.
You may also be interested in...
Australia Finds ‘Unacceptable’ Levels Of NDMA In 80% of Ranitidine Batches
Testing carried out by Australia's drug agency on batches of 34 ranitidine products marketed by 10 different sponsors has found high levels of NDMA contamination in the vast majority of cases. The agency is now considering tightening its oversight of all ranitidine drugs sold in Australia.
EMA Identifies Potential Sources Of Nitrosamine Contamination
As companies evaluate scores of products for the possible presence of nitrosamine impurities, the EU regulator has listed potential sources of contamination identified to date to help sponsors develop a risk-based approach for their evaluations.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.